Summary of minutes of EUCAST Steering Committee Meeting
Stockholm, Sweden, 9-10 July 2012

Attending
Dr Petra Apfalter PA EUCAST Austria
Dr Derek F.J. Brown DB Scientific Secretary United Kingdom
Dr Rafael Cantón RC Chairperson Spain
Prof Luc Dubruel LD CA-SFM France
Dr Christian Giske CG SRGA Sweden
Prof Gunnar Kahlmeter GK Clinical Data Co-ordinator Sweden
Prof Alasdair P. MacGowan AM BSAC United Kingdom
Dr Johan W. Mouton JM CRG The Netherlands
Dr Robert Skov RS EUCAST Denmark
Dr Martin Steinbakk MS NWGA Norway

Apologies
Prof Luis Martínez-Martínez LM EUCAST Spain
Prof Claude-James Soussy CS CA-SFM France

Present for sections 6, 10, 15, 18, 19
Dr Marc Struelens, Dr Liselotte Diaz Holberg, Dr Polya Rosin, Dr Gianfranco Spiteri ECDC, Sweden

Present for section 19
Dr Magnus Unemo MU Örebro University Hospital Sweden
Dr Cathy Ison (telephone link) CI HPA UK

Present for sections 4, 20-22
Dr Mair Powell MP MHRA UK

Present for section 10.3
Sheila Farnham, Anette Engelhardt, Giles Zambardi bioMérieux France

1 Chairman’s welcome
RC introduced the meeting as the new Chairman of EUCAST (since 5 April 2012). ECDC staff members were welcomed for joint sessions.

2 Minutes of meeting of 3-4 April 2012
With minor corrections the minutes were accepted as a correct record.

3 Matters arising from minutes of 3-4 April 2012
A proposal for a list of EUCAST projects on website was not accepted.
A list of agents recommended for testing is being discussed by ESGARS.
Agreed extension of GC representation on the Steering Committee will be implemented for 2013.

4 New agents
The current status of several new agents was discussed.

5 EUCAST rationale documents
Around 30 documents yet to be finished are at various stages.

6 Subcommittees
Antifungal susceptibility testing: Breakpoints for Aspergillus spp. with voriconazole are published and the process of setting breakpoints for isavuconazole and micafungin has been started.
Detection of resistance mechanisms of clinical and/or epidemiological importance: The first draft of a report is close to completion.

7 Breakpoint issues
A modified breakpoint table note on ampicillin/amoxicillin for pneumococci has been drafted.
For Enterobacteriaceae and amoxicillin-clavulanate breakpoints for UTI a document is being prepared to support the argument for higher breakpoints for UTI isolates.
Discussion of responses to the wide consultation on the table of ECOFFs for topical agents was deferred to the next Steering Committee meeting.
Ampicillin/amoxicillin MIC breakpoints for BLNAR H. influenzae are being discussed.

8 Organisms without EUCAST breakpoints
Comments from the breakpoint committee consultation on Campylobacter spp. were discussed and responses agreed. A revised document will be sent for wide consultation.
Discussions on methods and breakpoints for *Legionella* spp will include the ESCMID Study Group for Legionella Infections.

Comments from the breakpoint committee consultation on *Pasteurella multocida* were discussed and responses agreed. A revised document will be sent for wide consultation.

Following consultation with breakpoint committees it was agreed that there was no need for specific breakpoints for *Yersinia enterocolitica*.

### EUCAST methods

There is now a French translation of disk diffusion documents on the website. Minor discrepancies between the disk diffusion slide show and method description will be rectified.

### Implementation of EUCAST breakpoints

NACs are now established in most European countries, EUCAST breakpoints are being widely adopted and the EUCAST disk diffusion method is increasingly being adopted. New distribution maps on this issue were presented.

Revision of the “Preparedness of manufacturers” tables on the EUCAST website is underway. There was a presentation from bioMérieux on compliance with EUCAST guidelines.

### EUCAST website

Proposals for international MIC distribution website and ECOFFs were discussed.

### Publications

Papers explaining ECOFFs and “reporting as found” for Enterobacteriaceae are being prepared.

### Questionnaire on dosages

A draft summary document of current dosages has been prepared.

### EUCAST SOPs

SOPs on interaction of the Steering Committee with NACs and revision of breakpoints are being prepared.

### ESCMID

For ECCMID Berlin 2013 all EUCAST proposals have been agreed. The EUCAST-ESGARS Postgraduate Course in Madrid, September 2012 is considerably oversubscribed. There will be a Pk/Pd workshop in Athens on 8-11 October, 2012.

### EMA

Various EMA-related issues were discussed.

### CLSI

At the meeting in June 2012 it was agreed that colistin breakpoints would be set/reviewed in collaboration with EUCAST.

### ECDC

For the afternoon of 9 July 2012 the Steering Committee met at ECDC to cover items of particular interest to ECDC including implementation of EUCAST breakpoints, inclusion of ECDC microbiology focal points in EUCAST consultations, TATFAR, wider international involvement in MIC distributions and ECOFFs and an EFSA draft report on antimicrobial resistance surveillance.

### Neisseria gonorrhoeae

There was a detailed discussion of issues related to *N. gonorrhoeae*. It was agreed not to change cefixime breakpoints.

### New cephalosporin agent

Data in relation to breakpoints were discussed.

### Any other business

A study on the EUCAST disk diffusion test for streptococci was discussed.

### Next meetings

- **24.1**
  - 24-25 September 2012, Madrid, Spain
  - 12-13 November 2012, Rome, Italy
  - 4-5 February 2013, Brussels
  - 30 April -1 May 2013, Berlin (after ECCMID)
  - 8-9 July 2013, Stockholm

Unratified summary of minutes of meeting 9-10 July 2012. Prepared by DB, RC and GK